Abstracts tagged "Clinical research"

Abstract Number: L15 • 2014 ACR/ARHP Annual Meeting
Remission Induction By Etanercept in Enthesitis Related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy)
Ivan Foeldvari¹, Gerd Horneff², Kirsten Minden³, Ralf Trauzeddel⁴, J B. Kuemmerle-Deschner⁵, Klaus Tenbrock⁶, Gerd Ganser⁷ and Hans-Iko Huppertz⁸, ¹Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ²Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ³Chidlrens´ hospital, Charité University Medicine, Berlin, Germany, ⁴Pediatrics, Helios Clinics, Berlin, Germany, ⁵Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁶University Aachen, Aachen, Germany, ⁷Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ⁸Kinderklinik, Krinikum Bremen-Mitte, Bremen, Germany
Background/Purpose: Enthesitis related arthritis (ERA) is a Juvenile Idiopathic Arthritis category, clinically related to the syndrome of undifferentiated spondyloarthropathy in adults. This study is intended…
Abstract Number: 2230 • 2014 ACR/ARHP Annual Meeting
Treatment of Symptomatic Knee Osteoarthritis with Oral Salmon Calcitonin: Results from Two Phase 3 Randomized Clinical Trials
Morten Asser Karsdal¹, Anne C. Bay-Jensen², Asger Bihlet³, Peter Alexandersen⁴, Inger Byrjalsen³, Jeppe Andersen³, Bente J. Riis³ and Claus Christiansen³, ¹Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Center for Clinical and Basic Research, Vejle, Denmark
Background/Purpose: To evaluate the structure-modifying and symptom efficacy, as well as safety and tolerability of oral salmon calcitonin (sCT) formulated with a 5-CNAC carrier (a…
Abstract Number: 1553 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Philip J. Mease¹, Roy Fleischmann², Owen Davies³, Tommi Nurminen⁴ and Désirée van der Heijde⁵, ¹Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ²Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Early non-response to biologic therapy has been shown to be associated with a low probability of long-term response in rheumatoid arthritis1 and psoriasis2. However,…
Abstract Number: 1505 • 2014 ACR/ARHP Annual Meeting
The Biosimilar Landscape: A Systematic Review of Its Current Status
Niti Goel^1,2 and Kamali Chance³, ¹Rheumatology Center of Excellence, Quintiles, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Global Biosimilars Unit, Quintiles, Durham, NC
Background/Purpose In the last 5 years, the number of biosimilars in development for the treatment of immunologic diseases has increased as innovator etanercept (ETA), infliximab (IFX), adalimumab…
Abstract Number: 1436 • 2014 ACR/ARHP Annual Meeting
Impact of Depression on Clinical and Social Outcomes in Patients with Rheumatoid Arthritis: Comparative Study in Germany and Brazil
Harriet Morf¹, Olga Malysheva², G da Rocha³, Anna Beatriz Vargas³ and Christoph G. Baerwald², ¹Department of Internal Medicine, University Hospital, Leipzig, Germany, ²Rheumatology, University Hospital, Leipzig, Germany, ³Ambulatório de reumatologia da Policlínica Piquet Carneiro, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Background/Purpose Rheumatoid Arthritis (RA) can be associated with psychological disorders and especially depression. About 13 – 20 % of patients have clinical significant depression. It…
Abstract Number: 1256 • 2014 ACR/ARHP Annual Meeting
Clinical and Temporal Characterization of Anti-Jo-1 Positive Anti-Synthetase Syndrome: Preliminary Results of an International Multicentre Study
Lorenzo Cavagna¹, Miguel A González-Gay², Santos Castañeda-Sanz³, Franco Franceschini⁴, Paolo Airo⁵, Ilaria Cavazzana⁶, Laura Nuno⁷, Trinitario Pina Murcia², Francisco Javier Lopez Longo⁸, Norberto Ortego-Centeno⁹, Rossella Neri¹⁰, Simone Barsotti¹⁰, Enrico Fusaro¹¹, Simone Parisi¹², Giuseppe Paolazzi¹³, Giovanni Barausse¹³, Luca Quartuccio¹⁴, Elena Bartoloni-Bocci¹⁵, Carlo Selmi¹⁶, Carlo Alberto Scirè¹⁷, Elena Bravi¹⁸, Javier Bachiller Corral¹⁹, Lesley Ann Saketkoo²⁰, Gianluigi Bajocchi²¹, Raffaele Pellerito²², Marcello Govoni²³, Andreas Schwarting²⁴, Christof Specker²⁵, Carlomaurizio Montecucco¹ and Roberto Caporali²⁶, ¹Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario de La Princesa. Madrid. Spain, Madrid, Spain, ⁴AO Spedali Civili, Rheumatology and Clinical Immunology Unit, Brescia, Italy, ⁵Rheumatology and Clinical Immunology, Spedali Civili, AO Spedali Civili, Brescia, Italy, ⁶Rheumatology and Clinical Immunology Unit, AO Spedali Civili, Brescia, Italy, ⁷Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁸Rheumatology, Hospital Gregorio Marañón. Madrid, Madrid, Spain, ⁹Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹⁰Rheumatology Unit, University of Pisa, Pisa, Italy, ¹¹Department of Rheumatology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ¹²Rheumatology, Azienda Ospedaliera Città Della Salute e della Scienza, Turin, Italy, ¹³Rheumatology, Santa Chiara Hospital, Trento, Italy, ¹⁴Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ¹⁵Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ¹⁶Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy, ¹⁷Italian Society for Rheumatology, Milan, Italy, ¹⁸Internal Medicine, Rheumatology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy, ¹⁹Rheumatology, Hospital Ramon y Cajal, Madrid, Spain, ²⁰Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ²¹Department of Internal Medicine, Rheumatology Unit, Arcispedale S Maria Nuova. IRCCS, Reggio Emilia, Italy, ²²Rheumatology, Ospedale Mauriziano, Turin, Italy, ²³Clinical and Experimental Medicine, Section of Rheumatology, University of Ferrara, Ferrara, Italy, ²⁴Rheumatology, University Hospital Johannes-Gutenberg, Mainz, Germany, ²⁵Rheumazentrum Rhein-Ruhr e.V., St. Josef Krankenhaus (Kliniken Essen Süd), Universitätsklinikum Essen, Esssen, Germany, ²⁶Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
Background/Purpose: anti Jo-1 antibodies are the main marker of the antisynthetase syndrome (As), a connective tissue disease chiefly characterized by arthritis (A), myositis (M) and…
Abstract Number: 912 • 2014 ACR/ARHP Annual Meeting
A Consensus Hybrid Definition Using a Conjoint Analysis Is the Proposed As Response Criteria for Minimal and Moderate Improvement for Adult Polymyositis and Dermatomyositis Clincal Trials
Rohit Aggarwal¹, Lisa G. Rider², Nicolino Ruperto³, Nastaran Bayat², Brian Erman⁴, Brian M. Feldman⁵, Adam M. Huber⁶, Chester V. Oddis⁷, Ingrid E. Lundberg⁸, Anthony A. Amato, MD^9,10, Robert G. Cooper, MD, FRCP¹¹, Hector Chinoy¹², Maryam Dastmalchi¹³, David Fiorentino¹⁴, David Isenberg¹⁵, James D. Katz¹⁶, Andrew L. Mammen¹⁷, Marianne de Visser¹⁸, Steven R. Ytterberg¹⁹, Katalin Danko²⁰, Luca Villa²¹, Mariangela Rinaldi²¹, Howard Rockette²², Peter A. Lachenbruch², Frederick W. Miller² and Jiri Vencovsky, MD, DSc²³, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, ⁴Social and Scientific Systems, Inc., Durham, NC, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶IWK Health Centre, Halifax, NS, Canada, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁰Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹¹MRC/ARUK Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ¹²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹³Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁴Dermatology, Stanford University, Redwood City, CA, ¹⁵Centre for Rheumatology Research, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ¹⁶NIAMS, NIH, Bethesda, MD, ¹⁷Neurology and Medicine, Johns Hopkins University, Baltimore, MD, ¹⁸Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands, ¹⁹Rheumatology Division, Mayo Clinic, Rochester, MN, ²⁰Institute of Rheumatology, University of Debrecen, Hungary, Debrecen, Hungary, ²¹Pediatria II, Reumatologia, PRINTO, IRCCS Istituto G. Gaslini, Genova, Italy, ²²University of Pittsburgh, Pittsburgh, PA, ²³Institute of Rheumatology, Charles University, Prague, Czech Republic
Background/Purpose: To develop consensus on definitions of improvement (DOIs) for minimal and moderate improvement (and draft preliminary criteria for major improvement) in adult dermatomyositis (DM)…
Abstract Number: 1925 • 2013 ACR/ARHP Annual Meeting
Patient Satisfaction with an Associate Teaching Hospital Clinical Trial Unit In North-East London
Genevieve Casey¹, Carey Tierney², Hasan Tahir³, Simon Donnelly³ and Judith Bubbear³, ¹Barts and the London Medical School, London, United Kingdom, ²Whipps Cross Clinical Research Unit, Barts Health NHS Trust, London, United Kingdom, ³Rheumatology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Compared to patient satisfaction with general medical care little is known about patient satisfaction within clinical trials. Clinical trials are a time and resource…
Abstract Number: 1526 • 2013 ACR/ARHP Annual Meeting
Stable Clinical and MRI Response In Patients With Early Axial Spondyloarthritis After 3 Years Of Continuous Treatment With Etanercept, Data Of The Esther Trial
In-Ho Song¹, Kay-Geert A. Hermann², Hildrun Haibel¹, Christian Althoff³, Denis Poddubnyy⁴, Joachim Listing⁵, Anja Weiss⁶, Ekkehard Lange⁷, Bruce Freundlich⁸, Martin Rudwaleit⁹ and Joachim Sieper⁴, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶German Rheumatism Research Centre, Berlin, Germany, ⁷BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Endokrinologikum, Berlin, Germany
Background/Purpose: < style="text-align: justify;">In patients with early axial spondyloarthritis (SpA) with a disease duration of 10 years) where BASDAI50 response rates of 47%…
Abstract Number: 1386 • 2013 ACR/ARHP Annual Meeting
Intracellular Concentration Of Methotrexate Is Influenced By Polymorphisms Of Gamma-Glutamyl Hydrolase Gene In Japanese Patients With Rheumatoid Arthritis
Tatsuhiro Yamamoto, Mai Kawazoe, Emiko Shindo, Natsuki Fujio, Kotaro Shikano, Kanako Kitahara, Sei Muraoka, Makoto Kaburaki, Nahoko Tanaka, Kaichi Kaneko, Natsuko Kusunoki, Yoshie Kusunoki, Kenji Takagi, Tomoko Hasunuma, Hirahito Endo and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose: Methotrexate (MTX) is an anchor drug for treatment of rheumatoid arthritis (RA). Appropriate effective and/or tolerable doses of weekly pulse MTX therapy vary widely…
Abstract Number: 1339 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologics Agents For Patients With Rheumatoid Arthritis and Hepatitis B Carrier
Masahiro Tada¹, Tatsuya Koike², Akihiro Tamori³, Tadashi Okano¹, Yuko Sugioka¹, Kenji Mamoto¹, Kentaro Inui⁴ and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Hepatiology, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Biologics suppress hepatitis B virus (HBV) replication and play an important role in eradicating HBV by stimulating HBV-specific cytotoxic T-cell responses. We found that…
Abstract Number: 1334 • 2013 ACR/ARHP Annual Meeting
Predicted Versus Observed Radiographic Progression In a Rheumatoid Arthritis Randomized Trial
Adrian Levitsky¹, Kristina Forslind^2,3 and Ronald F. van Vollenhoven⁴, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Department of Clinical Sciences, Section of Rheumatology, Skåne University Hospital, Lund, Sweden, ³Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁴Karolinska Institute, Stockholm, Sweden
Background/Purpose: Radiographic progression is a key outcome in early RA. We previously developed a radiographic progression prediction method based on the patient’s report of symptom…
Abstract Number: 1030 • 2013 ACR/ARHP Annual Meeting
Readability of Participant Information and Consent Forms for Rheumatology Clinical Trial Participants
Stephen Hall¹, Gail Grant² and Christina Meyer², ¹Melbourne Rheumatology, Melbourne, Australia, ²emeritus research, melbourne, Australia
Background/Purpose: To determine the readability of written information (Participant Information and Consent Forms [PICS]) provided to clinical trial participants prior to enrolment into a clinical…
Abstract Number: 864 • 2013 ACR/ARHP Annual Meeting
Further Reduction In Nonvertebral Fracture Rate Is Observed Following 3 Years Of Denosumab Treatment: Results With Up To 7 Years In The Freedom Extension
Jonathan D. Adachi¹, Serge Ferrari², Carol Zapalowski³, Paul D. Miller⁴, Jean-Yves Reginster⁵, Ove Törring⁶, Nadia Daizadeh³, Andrea Wang³, Cynthia O'Malley⁷, Rachel B. Wagman³ and E. Michael Lewiecki⁸, ¹McMaster University, Hamilton, ON, Canada, ²Geneva University Hospital, Geneva, Switzerland, ³Amgen Inc., Thousand Oaks, CA, ⁴Colorado Center for Bone Research, Lakewood, CO, ⁵University of Liège, Liège, Belgium, ⁶Karolinska Institutet, Södersjukhuset, Stockholm, Sweden, ⁷Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁸New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM
Further Reduction in Nonvertebral Fracture Rate Is Observed Following 3 Years of Denosumab Treatment: Results With up to 7 Years in the FREEDOM ExtensionBackground/Purpose: Some…
Abstract Number: 731 • 2013 ACR/ARHP Annual Meeting
C3 Activation Is Associated With The Disease Activity Of Microscopic Polyangiitis
Dan Liu^1,2,3, Jin-song Zhou⁴, Qing-ping Chen⁴, Chao-yang Duan¹, Li Wang⁴, Yuan Jia³ and Ke Li¹, ¹Core Research Laboratory, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China, ²Department of Rheumatology and Immunology, The Fifth Hospital of Xi'an, Xi'an, China, ³Department of Rheumatology and Immunology,Clinical Immunology Center, Peking University People's Hospital, Beijing, China, ⁴Department of Rheumatology and Immunology, The Fifth Hospital of Xi'an, Xi’an, China
Background/Purpose: Microscopic polyangiitis (MPA) is the most common anti-neutrophil cytoplasmic antibodies(ANCA) associated small-vessel vasculitis with specificity of the ANCA to myeloperoxidase(MPO) of neutrophils. MPA mainly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].